bioGenous Biotechnology, Inc. is deeply committed to advancing foundational technological innovations in the organoid industry. It possesses globally leading, self-developed intellectual property in organoids and disease models, along with a GMP pharmaceutical-grade production technology system. Its main products include organoid culture reagents covering 23 types of normal tissues and 18 types of tumors, intelligent scenario-based equipment supporting the whole process of organoid construction, culture, and detection across multiple stages, and a flexible CRDMO technology platform tailored for pharmaceutical clients. Upholding the corporate vision of "Pioneering Pharmaceutical Innovation, Sharing Model Value," bioGenous is dedicated to providing standardized, pharmaceutical-grade upstream organoid solutions for the global biopharmaceutical industry. To date, it has served over 500 advanced international and domestic innovative pharmaceutical companies, research institutions, and medical organizations. Its products are exported to Europe and the United States, with cumulative sales exceeding one billion units.
The group's headquarters is located in Yangpu District, Shanghai, with R&D centers in Shanghai, Hong Kong, and Cambridge, UK. It has established branches and subsidiaries in multiple cities, including Beijing, Guangzhou, Wuhan, Nanjing, Suzhou (technical service base), Dezhou (northern production base), Nanchang, and Tianjin. The company has received strategic investments from AstraZeneca and the SDIC Fund.
Today, leveraging deep organoid resource development and AI data modeling, bioGenous is emerging as a leading enterprise driving the transition of innovative model methodologies from research-grade breakthroughs to pharmaceutical-grade applications.
